Latest news with #obesity
Yahoo
an hour ago
- Business
- Yahoo
Novo Nordisk (NVO) Sell-Off Wipes Billions in Market Value
July 30- Novo Nordisk (NYSE:NVO) continued to slide 7% on Wednesday after the Danish drugmaker cut its full?year outlook. Slower growth in its obesity franchise, led by semaglutide, weighed down the company's performance. Warning! GuruFocus has detected 1 Warning Sign with NVO. The company now sees sales rising 8%14% and operating profit up 10%16% on a currency?adjusted basis, down from prior forecasts of 13%21% and 16%24%. Management cited weaker U.S. demand for Wegovy and Ozempic amid rising competition from compounded GLP?1 therapies. Investors dumped shares fast. The sell-off erased an estimated $70 billion in market value, slashing Novo Nordisk's valuation to around $287 billion, down from roughly $357 billion a day earlier. Technical indicators show heightened selling pressure, with the 14?day Relative Strength Index at 26.4below the 30?level that often signals an oversold stock. NVO remains 64.9% below its record intraday high of $148.15 reached in June 2024. Some analysts maintain a positive stance despite the outlook cut. They point to Novo Nordisk's dominant GLP?1 pipeline and expect oral Wegovy approvals to support long?term growth, though they warn that near?term volatility may persist. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Business
- Yahoo
Clearmind Medicine Files International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease
Vancouver, Canada, July 30, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ('Clearmind' or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the filing of a new international patent application under the Patent Cooperation Treaty (PCT). The application covers its innovative combination therapy of MEAI (5-methoxy-2-aminoindane and N-Acylethanolamines) and Palmitoylethanolamide (PEA). This proprietary combination is designed to address two significant global health challenges: obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). According to the World Health Organization, obesity affects over 890 million people worldwide and is a leading risk factor for a range of chronic conditions. Meanwhile, non-alcoholic fatty liver disease (NAFLD), which is closely linked to metabolic disorders and poor long-term outcomes, is estimated to impact more than 30% of the global adult population. Despite the scale of these problems, treatment options remain limited. The Company believes that its novel approach has the potential to offer a safe and effective therapeutic alternative, leveraging the unique pharmacological profile of MEAI alongside the anti-inflammatory and neuroprotective properties of PEA. This patent filing is part of Clearmind's ongoing collaboration with SciSparc Ltd. (Nasdaq: SPRC), a clinical-stage specialty pharmaceutical company developing therapies for central nervous system disorders. 'Our goal is to bring meaningful innovation to areas with high unmet medical need,' said Dr. Adi Zuloff-Shani, CEO of Clearmind. 'This patent filing reflects our commitment to developing novel, science-backed treatments that can potentially improve the lives of millions struggling with obesity and fatty liver disease.' About Clearmind Medicine Inc. Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. The Company's intellectual portfolio currently consists of nineteen patent families including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio. Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol 'CWY0.' For further information visit: or contact: Investor Relationsinvest@ Telephone: (604) 260-1566US: CMND@ General InquiriesInfo@ Forward-Looking Statements: This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as 'expects,' 'anticipates,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates' and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses its belief that its novel approach of the combination therapy of MEAI and PEA has the potential to offer a safe and effective therapeutic alternative, its goal to to bring meaningful innovation to areas with high unmet medical need and its commitment to developing novel, science-backed treatments that can potentially improve the lives of millions struggling with obesity and fatty liver disease. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management's expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's reports filed from time to time with the Securities and Exchange Commission ('SEC'), including, but not limited to, the risks detailed in the Company's annual report on Form 20-F for the fiscal year ended October 31, 2024 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
Yahoo
3 hours ago
- Business
- Yahoo
SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease
TEL AVIV, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) ('Clearmind') has led to the filing of a new international patent application under the Patent Cooperation Treaty. The application covers its innovative combination therapy of 5-methoxy-2-aminoindane and N-Acylethanolamines (MEAI) and Palmitoylethanolamide (PEA). This proprietary combination is designed to address two significant global health challenges: obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). According to the World Health Organization, obesity affects over 890 million people worldwide and is a leading risk factor for a range of chronic conditions. Meanwhile, non-alcoholic fatty liver disease (NAFLD), which is closely linked to metabolic disorders and poor long-term outcomes, is estimated to impact more than 30% of the global adult population, according to the article titled 'Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons,' published in August 2023. Despite the scale of these problems, treatment options remain limited. According to Clearmind, the novel approach has the potential to offer a safe and effective therapeutic alternative, leveraging the unique pharmacological profile of MEAI alongside the anti-inflammatory and neuroprotective properties of PEA. This latest development adds to multiple patent applications already filed in the U.S. and other countries as part of the ongoing SciSparc-Clearmind collaboration. About SciSparc Ltd. (Nasdaq: SPRC): SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc's focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation; and SCI-210 for the treatment of autism and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds' oil-based products on the Marketplace. About Clearmind Medicine Inc. (Nasdaq: CMND) (FSE: CWY) Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. Clearmind's intellectual portfolio currently consists of 19 patent families including 31 granted patents. For further information visit: Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, the Company is using forward looking statements when discussing the potential benefits and advantages of the new patent application, that this proprietary combination is designed to address two significant global health challenges: obesity and MASLD, and that it has the potential to offer a safe and effective therapeutic alternative, leveraging the unique pharmacological profile of MEAI alongside the anti-inflammatory and neuroprotective properties of PEA. Since such statements deal with future events and are based on SciSparc's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in SciSparc's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the 'SEC') on April 24, 2025, and in subsequent filings with the SEC. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise. Investor Contact:IR@ +972-3-6167055Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
4 hours ago
- Health
- Medscape
Obese Physicians Tackle Stigma, Promote Compassionate Care
Obesity affects a large proportion of US adults, including physicians themselves. And while obesity is increasingly recognized as a chronic disease, bias and stigma remain widespread in healthcare. Medscape Medical News spoke with three physicians whose personal experiences with weight and health challenges are informing how they practice medicine, counsel patients, and address systemic bias within their profession. Personal Struggles With Obesity Margarita Macias, MD, a pediatrician with BCA Medical Associates in Roswell, New Mexico, started with a BMI of 34 while struggling to help her teenage patients with obesity. 'I didn't like the way I looked or felt,' Macias said. 'I was sluggish, tired all the time, was beginning to have sleep apnea, and had poor exercise tolerance.' Equally evident was her professional dissonance. 'I felt like a fraud or a hypocrite talking to my obese patients about health risks while being obese myself,' she said. Tro Kalayjian, DO, chief medical officer of Toward Health and a board-certified physician in internal medicine and obesity medicine, faced a more dramatic situation. 'I weighed 350 pounds and was facing the same chronic diseases I was treating in my patients,' he said. 'My role as a physician forced me to confront the failures of conventional advice.' After losing over 150 pounds, Kalayjian said, '[My journey] fundamentally reshaped how I view nutrition, obesity, and chronic disease.' Ramón Tallaj, MD, founder and chairman of SOMOS Community Care, describes recognizing his own hypertension while leading a network serving over 1 million underserved patients. 'I was fully consumed by caring for others while quietly ignoring signs in my own body,' he recalled. Tallaj's leadership role also revealed other underlying issues at play. 'I observed that chronic conditions like hypertension, diabetes, and obesity are shaped not only by personal choices but by systemic factors: limited access to healthy foods, lack of safe spaces for exercise, cultural barriers, language gaps, and financial strain. This is not just a clinical problem; it is a social and economic crisis that repeats itself generation after generation.' Evidence of Healthcare Bias Kalayjian described experiencing weight bias 'at every level. Obese physicians are often viewed as less credible, even by peers who fail to recognize the complexity of the disease. Patients sometimes assume you cannot help them if you struggle yourself.' Tallaj identified a particular form of professional bias. 'In medicine, there's an implicit expectation that knowledge equates to immunity — that we should be exempt from chronic conditions. This bias is prevalent within the system, among colleagues, and even within ourselves,' he said. Research supports these physicians' experiences with professional stigma. A 2021 systematic review and meta-analysis published in Obesity found that healthcare professionals demonstrate both implicit and explicit weight bias toward people with obesity. The analysis identified bias among physicians, nurses, dietitians, psychologists, and other allied health professionals based on standardized tools such as the Fat Phobia Scale and Antifat Attitudes Scale. A 2020 international consensus statement published in Nature Medicine described obesity as a complex, chronic disease driven by genetic, biological, and environmental factors. The authors reported that weight discrimination affects 19%-42% of adults with obesity, with prevalence being the highest among individuals with higher BMI and among women. Shifting Clinical Approaches 'I approach it with more compassion because I know the struggle,' Macias said. 'Many parents have been inspired by my progress, having seen me once obese. Many have returned with their kids after starting their own family weight loss journey with significant success.' Kalayjian's approach transformed completely. 'I now approach obesity as a neurohormonal disease influenced by processed foods, environment, and metabolic dysfunction,' he said. 'I emphasize compassion and education, not willpower.' Emphasizing metabolic health vs weight loss is also a good approach, according to Tallaj. 'We emphasize building lean muscle mass, optimizing protein intake, stabilizing blood sugar variability, addressing sleep quality, and regulating stress,' he said. 'Muscle serves as the primary site for glucose disposal, improves insulin sensitivity, and supports vascular health.' Acknowledging the Complexities of Obesity All three physicians challenged the oversimplified willpower narrative. Macias identified multiple contributing factors. 'Many struggle with depression, anxiety, poor self-image, or it is hereditary,' she said. 'If one parent is obese, 50% of their children could be obese; 75% if both parents are obese.' Kalayjian argued that the medical profession remains 'stuck in an outdated energy balance model. Medical education is influenced by corporate interests that perpetuate myths about calories in, calories out. Obesity involves disrupted appetite regulation, metabolic damage, and food addiction in many cases.' Tallaj provided a systems perspective: 'The medical community still reduces obesity to personal failure — eat less, move more. This is dangerous oversimplification. Obesity is influenced by genetics, metabolic adaptation, hormonal drivers, mental health, trauma, cultural norms, and environmental factors including food deserts and socioeconomic barriers that severely limit access to nutritious options.' Challenging Colleagues When confronting colleagues who link obesity to patient willpower, these physicians respond with evidence. 'I remind them that no one chooses to be obese,' Kalayjian said. 'Willpower fails when fighting biology. If willpower worked, we would not have an epidemic.' Tallaj draws clinical parallels: 'No one blames patients with cancer or autoimmune disease for lacking discipline — yet we shame people with obesity in ways that are scientifically wrong and deeply harmful,' he said. 'Obesity involves powerful biological feedback mechanisms. Weight loss triggers metabolic adaptations that resist further weight reduction.' Recommended Changes in Medical Culture Tallaj advocates for redefining clinical metrics. 'We need to stop focusing solely on BMI,' he said. 'We need to train doctors to consider muscle strength, metabolic flexibility, inflammation, and blood sugar stability — these factors tell us far more about long-term health than weight alone.' Macias emphasizes compassionate engagement: 'I would like to see colleagues approach it with compassion over reprimand or scare tactics. Take time to understand their struggle. There almost always is more than just a lack of willpower or discipline. Unlocking that and helping them through the root of the problem is sometimes all it takes to help them succeed.' Kalayjian calls for systemic change: 'I want to see an end to blame-based language. We need to train providers in the true science of obesity and nutrition. Provider wellness must include addressing food addiction and metabolic health, not just promoting vague notions of self-care.' Tallaj highlights physician wellness as professional responsibility. 'We need to eliminate the quiet shame that still exists when doctors struggle with mental health, burnout, weight issues, or chronic conditions,' he said. 'We must cultivate a medical culture where physicians prioritize their own health. Healthy physicians lead better, counsel better, and earn greater trust from patients.' The Path Forward Macias, whose BMI decreased from 34 to 27, emphasized the therapeutic value of supportive relationships. 'When patients feel that their health provider is their supportive ally in their weight loss journey, it makes a world of difference physically, mentally, and emotionally,' she said. This practice can be reinforced through organizational leadership, Tallaj said. 'Prevention requires a system of care that meets people where they are, long before disease takes hold,' he said. 'We cannot lead our patients to wellness if we are not living the principles we ask them to follow.' This evolution represents a shift from traditional approaches that may inadvertently perpetuate stigma toward evidence-based, compassionate care that acknowledges obesity as a complex, chronic disease requiring comprehensive treatment addressing both individual and systemic factors. Reflecting on how his own experience with obesity transformed his approach to care, Kalayjian said, 'Patients need tools to change their physiology and environment, not lectures about calories.'
Globe and Mail
6 hours ago
- Business
- Globe and Mail
Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025
SAN DIEGO, July 30, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) ('Skye'), a clinical-stage biotechnology company focused on advancing new therapeutic pathways for obesity and other metabolic health disorders, will host a conference call on Thursday, August 7, 2025 at 1:30 p.m. PT/4:30 p.m. ET to discuss its second quarter 2025 financial results. The Company will issue its financial results and business update press release after the market closes on the same day. The live webcast of the call can be accessed at the Skye Investor Relations website, along with the company's earnings press release, financial tables, and investor presentation. Please join the call 5-10 minutes prior to the scheduled start time. Following the call, a replay will be available at the same website. About Skye Bioscience Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2 clinical trial ( NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: Connect with us on X and LinkedIn. CONTACTS Investor Relations ir@ (858) 410-0266 LifeSci Advisors, Mike Moyer mmoyer@ (617) 308-4306 Media Inquiries LifeSci Communications, Michael Fitzhugh mfitzhugh@ (628) 234-3889
